Trial · NCT01677741
Participant flow40
How many started, completed or left each group, period by period.
1 to 20 of 40
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1 (Dose Escalation): Dabrafenib Treatment (3 mg/kg) | 3 | |
| Overall Study | STARTED | Part 1 (Dose Escalation): Dabrafenib Treatment (3.75 mg/kg) | 10 | |
| Overall Study | STARTED | Part 1 (Dose Escalation): Dabrafenib Treatment (4.5 mg/kg) | 8 | |
| Overall Study | STARTED | Part 1 (Dose Escalation): Dabrafenib Treatment (5.25 mg/kg) | 6 | |
| Overall Study | STARTED | Part 2 (Tumor Specific Expansion): Cohort 1 Low-Grade Gliomas (LGG) | 17 | |
| Overall Study | STARTED | Part 2 (Tumor Specific Expansion): Cohort 2 High-Grade Gliomas (HGG) | 28 | |
| Overall Study | STARTED | Part 2 (Tumor Specific Expansion): Cohort 3 Langerhans Cell Histiocytosis (LCH) | 11 | |
| Overall Study | STARTED | Part 2 (Tumor Specific Expansion): Cohort 4 Miscellaneous Tumors (Other) | 2 | |
| Overall Study | DLT Evaluable Population | Part 1 (Dose Escalation): Dabrafenib Treatment (3 mg/kg) | 3 | |
| Overall Study | DLT Evaluable Population | Part 1 (Dose Escalation): Dabrafenib Treatment (3.75 mg/kg) | 10 | |
| Overall Study | DLT Evaluable Population | Part 1 (Dose Escalation): Dabrafenib Treatment (4.5 mg/kg) | 8 | |
| Overall Study | DLT Evaluable Population | Part 1 (Dose Escalation): Dabrafenib Treatment (5.25 mg/kg) | 6 | |
| Overall Study | DLT Evaluable Population | Part 2 (Tumor Specific Expansion): Cohort 1 Low-Grade Gliomas (LGG) | 0 | |
| Overall Study | DLT Evaluable Population | Part 2 (Tumor Specific Expansion): Cohort 2 High-Grade Gliomas (HGG) | 0 | |
| Overall Study | DLT Evaluable Population | Part 2 (Tumor Specific Expansion): Cohort 3 Langerhans Cell Histiocytosis (LCH) | 0 | |
| Overall Study | DLT Evaluable Population | Part 2 (Tumor Specific Expansion): Cohort 4 Miscellaneous Tumors (Other) | 0 | |
| Overall Study | PK Population | Part 1 (Dose Escalation): Dabrafenib Treatment (3 mg/kg) | 3 | |
| Overall Study | PK Population | Part 1 (Dose Escalation): Dabrafenib Treatment (3.75 mg/kg) | 10 | |
| Overall Study | PK Population | Part 1 (Dose Escalation): Dabrafenib Treatment (4.5 mg/kg) | 8 | |
| Overall Study | PK Population | Part 1 (Dose Escalation): Dabrafenib Treatment (5.25 mg/kg) | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01677741/flow